WASHINGTON (AP) Health advisers met Thursday to review more than a half-dozen peptides, unproven substances that have become a growing wellness trend despite little evidence they are safe or effective
FAQs Q1
For some GLP-1 users, there is an unexpected side effect bad breath, which is behind the increase in breath freshener sales
We found between 43 and 2109 predicted neoepitopes with weak or strong HLA class I binding affinity in each patient (median 217) in early disease
Jastreboff, et al., 'Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA', Lancet , vol
They are also not the whole story